Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
Acute myeloid leukemia
FLT3 inhibitor
FLT3 mutations
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
30
04
2021
accepted:
26
07
2021
pubmed:
8
8
2021
medline:
21
10
2021
entrez:
7
8
2021
Statut:
ppublish
Résumé
Until recently, no effective targeted therapies for FLT3-mutated (FLT3 We evaluated the Japanese subgroup (n = 48) of the ADMIRAL trial, which included 33 patients randomized to 120-mg/day gilteritinib and 15 randomized to SC. Median OS was 14.3 months in the gilteritinib arm and 9.6 months in the SC arm. The complete remission/complete remission with partial hematologic recovery rate was higher in the gilteritinib arm (48.5%) than in the SC arm (13.3%). After adjustment for drug exposure, fewer adverse events (AEs) occurred in the gilteritinib arm than in the SC arm. Common grade ≥ 3 AEs related to gilteritinib were febrile neutropenia (36%), decreased platelet count (27%), and anemia (24%). Findings in Japanese patients are consistent with those of the overall ADMIRAL study population.
Sections du résumé
BACKGROUND
BACKGROUND
Until recently, no effective targeted therapies for FLT3-mutated (FLT3
METHODS
METHODS
We evaluated the Japanese subgroup (n = 48) of the ADMIRAL trial, which included 33 patients randomized to 120-mg/day gilteritinib and 15 randomized to SC.
RESULTS
RESULTS
Median OS was 14.3 months in the gilteritinib arm and 9.6 months in the SC arm. The complete remission/complete remission with partial hematologic recovery rate was higher in the gilteritinib arm (48.5%) than in the SC arm (13.3%). After adjustment for drug exposure, fewer adverse events (AEs) occurred in the gilteritinib arm than in the SC arm. Common grade ≥ 3 AEs related to gilteritinib were febrile neutropenia (36%), decreased platelet count (27%), and anemia (24%).
CONCLUSION
CONCLUSIONS
Findings in Japanese patients are consistent with those of the overall ADMIRAL study population.
Identifiants
pubmed: 34363558
doi: 10.1007/s10147-021-02006-7
pii: 10.1007/s10147-021-02006-7
pmc: PMC8522999
doi:
Substances chimiques
Aniline Compounds
0
Pyrazines
0
gilteritinib
0
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2131-2141Informations de copyright
© 2021. The Author(s).
Références
Lancet Oncol. 2017 Aug;18(8):1061-1075
pubmed: 28645776
Leukemia. 2011 Jun;25(6):939-44
pubmed: 21331073
Int J Hematol. 2019 Dec;110(6):665-674
pubmed: 31473943
Blood. 2004 May 15;103(10):3669-76
pubmed: 14726387
Blood. 2017 Jan 12;129(2):257-260
pubmed: 27908881
Cancer Sci. 2018 Oct;109(10):3235-3244
pubmed: 30039554
Blood. 2011 Mar 24;117(12):3294-301
pubmed: 21270442
Leukemia. 2015 Dec;29(12):2390-2
pubmed: 26108694
Lancet Oncol. 2019 Jul;20(7):984-997
pubmed: 31175001
Br J Haematol. 2001 Jan;112(1):127-37
pubmed: 11167793
Int J Hematol. 2019 Nov;110(5):566-574
pubmed: 31432396
Leukemia. 1997 Oct;11(10):1605-9
pubmed: 9324277
Invest New Drugs. 2017 Oct;35(5):556-565
pubmed: 28516360
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
Leuk Res. 2004 Jul;28(7):679-89
pubmed: 15158089
Leukemia. 2019 Feb;33(2):299-312
pubmed: 30651634
Leukemia. 2017 Jun;31(6):1306-1313
pubmed: 28138160
Haematologica. 2015 Mar;100(3):e77-9
pubmed: 25425690
Am J Hematol. 2018 Jun 15;:
pubmed: 29905379
Blood. 2005 Feb 1;105(3):986-93
pubmed: 15459012
N Engl J Med. 2019 Oct 31;381(18):1728-1740
pubmed: 31665578
J Clin Oncol. 2005 Mar 20;23(9):1969-78
pubmed: 15632409
Blood. 2001 Apr 15;97(8):2434-9
pubmed: 11290608
Int J Hematol. 2012 Aug;96(2):171-7
pubmed: 22851055
Blood. 2017 Jun 29;129(26):3403-3406
pubmed: 28546144
J Mol Diagn. 2003 May;5(2):96-102
pubmed: 12707374
Leukemia. 1998 Sep;12(9):1333-7
pubmed: 9737679
Jpn J Clin Oncol. 2016 Apr;46(4):394
pubmed: 27004901
Nature. 2012 Apr 15;485(7397):260-3
pubmed: 22504184
Blood. 2008 Mar 1;111(5):2527-37
pubmed: 17965322
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
J Clin Oncol. 2010 Oct 1;28(28):4339-45
pubmed: 20733134
Leukemia. 2014 Aug;28(8):1586-95
pubmed: 24487413